1. Field of the Invention
The present disclosure generally relates to respiratory therapies. More particularly, the disclosure generally relates to a method and system for high frequency upper chest wall oscillation therapy.
2. Description of the Relevant Art
Subjects who are unable to mobilize their own lung secretions without assistance (subjects with, for example, chronic obstructive pulmonary disease (COPD)) are exceedingly common, which together account for over 1 million hospitalizations each year in the United States alone. Beta agonists, anti-cholinergics, and corticosteroids delivered in aerosolized forms are recommended in the treatment of COPD. These medications rely on deposition into distal airspaces to suppress airway inflammation or promote bronchodilation. Excessive mucous production and impaired airway mucociliary clearance can lead to airway plugging, and thereby reduce the deposition of and response to aerosolized medications. These considerations highlight the need for therapies that clear airways of mucus in the acute management of diseases such as cystic fibrosis, bronchiectasis (and other severe form of COPD), and certain neuromuscular diseases.
Manual percussion techniques of chest physiotherapy have been used for a variety of diseases, such as cystic fibrosis, emphysema, and chronic bronchitis, to remove excess mucus that collects in the lungs. To bypass dependency on a caregiver to provide this therapy, chest compression and oscillation devices have been developed to produce High Frequency Chest Wall Oscillation (HFCWO), a very successful method of airway clearance. High frequency chest wall oscillation (HFCWO) creates high velocity, low amplitude oscillation energy when applied through a vest worn over the thorax, and is used for airway mucus clearance in patients with cystic fibrosis, bronchiectasis, and neuromuscular disorders. Studies in patients with cystic fibrosis suggest that HFCWO applied via a vest is as effective as other modes of airway mucus clearance, including hand-held devices (e.g., flutter devices) and conventional chest physiotherapy. HFCWO offers the advantage that it can be performed in acutely ill patients who may be unable to use hand-held devices effectively, such as early in the course of hospitalization. Moreover, HFCWO can be performed without the assistance from trained health care personnel, and may therefore offer a practical advantage compared to chest physiotherapy.
Professional healthcare environments are required to constantly be vigilant regarding sanitation and cross contamination between patients. To this end medical equipment must be sanitized before being used again. However, sanitizing equipment is typically time consuming and/or expensive. As such much of the equipment used in healthcare environments which comes into direct contact with subjects is disposable (or covered by disposable sheaths). It is typically much easier and/or less expensive to throw away equipment which comes into contact with subjects as opposed to cleaning the equipment.
As such, it may advantageous to form a wearable HFCWO system with one or more disposable portions.
In some embodiments, a system and/or method may include an inner wearable harness worn, during use, on a torso of a subject. The system may include a plurality of engines which when activated apply an oscillation force to at least one treatment area of the subject. At least some of the plurality of engines may be releasably couplable to the inner wearable harness. The system may include a positioning system which allows positioning at least one of the plurality of engines such that the oscillation force is applied to at least one of the treatment areas of the subject. The oscillation force may mobilize, during use, at least some secretions in an airway within the subject substantially adjacent the treatment area. The system may include an outer harness worn, during use, on a torso of a subject. The outer wearable harness, when activated, adjusts the oscillation force applied by at least some of the activated plurality of engines to the treatment area.
Advantages of the present invention may become apparent to those skilled in the art with the benefit of the following detailed description of the preferred embodiments and upon reference to the accompanying drawings.
While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawings and may herein be described in detail. The drawings may not be to scale. It should be understood, however, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the present invention as defined by the appended claims.
The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description. As used throughout this application, the word “may” is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). The words “include,” “including,” and “includes” indicate open-ended relationships and therefore mean including, but not limited to. Similarly, the words “have,” “having,” and “has” also indicated open-ended relationships, and thus mean having, but not limited to. The terms “first,” “second,” “third,” and so forth as used herein are used as labels for nouns that they precede, and do not imply any type of ordering (e.g., spatial, temporal, logical, etc.) unless such an ordering is otherwise explicitly indicated. For example, a “third die electrically connected to the module substrate” does not preclude scenarios in which a “fourth die electrically connected to the module substrate” is connected prior to the third die, unless otherwise specified. Similarly, a “second” feature does not require that a “first” feature be implemented prior to the “second” feature, unless otherwise specified.
Various components may be described as “configured to” perform a task or tasks. In such contexts, “configured to” is a broad recitation generally meaning “having structure that” performs the task or tasks during operation. As such, the component can be configured to perform the task even when the component is not currently performing that task (e.g., a set of electrical conductors may be configured to electrically connect a module to another module, even when the two modules are not connected). In some contexts, “configured to” may be a broad recitation of structure generally meaning “having circuitry that” performs the task or tasks during operation. As such, the component can be configured to perform the task even when the component is not currently on. In general, the circuitry that forms the structure corresponding to “configured to” may include hardware circuits.
Various components may be described as performing a task or tasks, for convenience in the description. Such descriptions should be interpreted as including the phrase “configured to.” Reciting a component that is configured to perform one or more tasks is expressly intended not to invoke 35 U.S.C. § 112 paragraph (f), interpretation for that component.
The scope of the present disclosure includes any feature or combination of features disclosed herein (either explicitly or implicitly), or any generalization thereof, whether or not it mitigates any or all of the problems addressed herein. Accordingly, new claims may be formulated during prosecution of this application (or an application claiming priority thereto) to any such combination of features. In particular, with reference to the appended claims, features from dependent claims may be combined with those of the independent claims and features from respective independent claims may be combined in any appropriate manner and not merely in the specific combinations enumerated in the appended claims.
It is to be understood the present invention is not limited to particular devices or biological systems, which may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include singular and plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a linker” includes one or more linkers.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
The term “compression” as used herein generally refers to the application of balanced inward (e.g., “pushing”) forces to different points on a material or structure.
The term “connected” as used herein generally refers to pieces which may be joined or linked together.
The term “coupled” as used herein generally refers to pieces which may be used operatively with each other, or joined or linked together, with or without one or more intervening members.
The term “directly” as used herein generally refers to one structure in physical contact with another structure, or, when used in reference to a procedure, means that one process effects another process or structure without the involvement of an intermediate step or component.
The term “engine” as used herein generally refers to a machine designed to convert one form of energy into mechanical energy (e.g., electric motors, sonic wave generators, etc.).
The phrase “oscillation force” as used herein generally refers to a vibrational force, or a vibrational wave effect or wave form.
The term “pressure” as used herein generally refers to a force applied substantially perpendicular to a surface of an object.
Portable High Frequency Physiological Oscillator
Chest physiotherapy with bronchial drainage is a known treatment for mobilization and removal of airway secretions in many types of respiratory dysfunction especially in chronic lung disease (e.g., cystic fibrosis, brochiectasis, bronchitis, primary ciliary dyskinesia syndrome). Chest physiotherapy has been demonstrated to be effective in maintaining pulmonary function and prevention or reduction of respiratory complications in patients with chronic respiratory diseases. In some embodiments, a system and/or method may include clearing a biological airway. Biological airways may include any portion of the respiratory system including, but not limited to, trachea, bronchi, bronchioles, and alveoli.
The method may include positioning a wearable system on a subject. The method may include adjusting the wearable system such that an oscillation force is applied to at least a first zone and to at least a second zone of the subject (e.g., and possibly more zones). In some embodiments, an oscillation force may include a vibrational force, or a vibrational wave effect or wave form.
In some embodiments, the first zone 220a may be proximate to and below a collarbone of the subject (e.g., as depicted in
In some embodiments, mobilizing secretions may include generating increased airflow velocities and/or percussive or oscillation forces resulting in cough-like shear forces. In some embodiments, mobilizing secretions may include decreasing a viscosity of at least some secretions in an airway within the subject substantially adjacent the first and/or second zone. Mobilizing secretions may assist subjects to move retained secretions from smaller airways to larger airways where they may move more easily via coughing. In some embodiments, secretions may include what is generally referred to as mucus. Mucus may include water, ions, soluble mediators, inflammatory cells, and/or secreted mucins. In some embodiments, secretions may include any fluids (e.g., excessive fluids) potentially blocking subject airways.
In some embodiments, adjusting the wearable system may include adjusting fastening systems which couple the wearable system to the subject. In some embodiments, the wearable system may be adjustable at least across a chest and/or portion of a torso of a subject (e.g., as depicted in
In some embodiments, engines may be repositioned or adjusted relative to a subject using a system (e.g., by a doctor) which inhibits a subject from repositioning the engines once positioned. For example, a wearable garment may include a plurality of pockets or containers which engines may be positioned in and then sealed in.
In some embodiments, the system may include a wearable system (e.g., as depicted in
The engines may be positionally coupled or directly attached to the bands and/or system using a number of means known such that the engines may be repositioned during use as appropriate for individual subjects. In some embodiments, a hook and loop system may be used to couple the engines to a wearable system such that the engines are repositionable.
In some embodiments, the wearable system 100 may include multiple engines 110 (e.g., eight or more engines). The system may include at least four engines 110, at least six engines 110, or at least eight engines 110 (e.g., as depicted in
In some embodiments, the system 100 may include a control unit 140. The method may include activating at least the first engine using the control unit 140. The control unit may control activation/deactivation/adjustment of all of the engines of the system 100. In some embodiments, the control unit 140 may be couplable to the system 100 (e.g., using a flap of material which may be used to cover and protect the control unit as depicted in
In some embodiments, a method may include modifying the treatment parameters (e.g. amplitude, frequency, and time for each engine). Each engine may be programmed, using physical hardware control unit or software to run a custom cycle. This programming may be performed by the subject. In addition, the system may provide a physician or caregiver with the ability to prescribe a defined treatment and to inhibit the user from modifying the treatment settings (e.g. lock-out feature w/password, pin code, etc.).
In some embodiments, the method and/or system may adaptively modify the treatment protocol based on subject and/or physician feedback. For example, a subject enters mucus secretion levels after each treatment and the system adaptively optimizes the treatment settings over time.
In some embodiments, the method and/or system may monitor compliance for each subject, including parameters run, time of treatment, information. For example, the system could monitor (in real-time) the treatment time of day and any subject feedback. This could be accomplished through hardware or software (e.g. a web-based subject/physician portal which links w/Bluetooth to each vest). The information may be provided to the subject, physician, insurance company or other third-party.
In some embodiments, the system 100 may include at least one battery 150. The method may include powering at least the first engine 110a using one or more batteries 150 coupled or directly attached to the wearable system. In some embodiments, a battery 150 may include a rechargeable battery and/or a disposable battery. The battery 150 may include two or more batteries. The batteries 150 may be easily swapped out whether rechargeable or disposable. The battery 150 may be coupled or directly attached to the system 100 (e.g., using a flap of material which may be used to cover and protect the battery as depicted in
In some embodiments, the system may be self-contained. The system may be self-contained such that a subject may wear the system 100 and move freely and in a substantially unrestricted manner. The system may be self-contained such that a subject may wear the system 100 while functioning and not physically connected to any external devices (e.g., air pumps).
Upper Chest Portable High Frequency Physiological Oscillator
In some embodiments, a system and/or method may include clearing a biological airway(s). As discussed though even wearable systems as described herein may not be sufficient to assist a subject in fully clearing the subject's biological airway. In some instances secretions may be moved out of the lungs but not high enough into the major bronchial tubes and/or trachea such that a subject may evacuate the secretions from the subject (especially with the reduced air capacity of the subject who need to employ systems as described herein). It would be beneficial to have a system which works alone or in combination with the vest/harnesses described herein to further move a subject's secretions out of the subject's airways.
In some embodiments, the method may include positioning a wearable system around a subject's neck. The wearable system may be coupled or directly attached to another wearable garment such that the wearable system is positioned substantially around at least a portion of the subject's neck. The method may include adjusting the wearable system such that an oscillation force is applied to at least an upper first zone of the subject. The upper first zone may be proximate to a collarbone of the subject and proximate to a juxtaposition of the subject's bronchial tubes and trachea on a first side of the subject. The method may include applying the oscillation force to at least upper first zone using an upper first engine. The method may include mobilizing at least some secretions in an airway within the subject substantially adjacent the first zone so that it may be expelled by the subject.
In some embodiments, the method may include adjusting the wearable system such that the oscillation force is applied to at least an upper second zone of the subject. The upper second zone may be proximate to the collarbone of the subject and proximate to the juxtaposition of the subject's bronchial tubes and trachea. The upper second zone may be positioned on a second side of the subject, wherein the second side is on an opposing side of the subject from the first side. The method may include applying the oscillation force to the at least upper second zone using an upper second engine. The upper second engine may include at least one (e.g., three) engines.
In some embodiments, the wearable system 300 may include adjustable fastening systems 320 which couple the wearable system to the subject. Adjustable fastening systems may include snaps buckles, Velcro, etc.
In some embodiments, the system 300 may include a control unit 140 (e.g., a control unit of the system 300 may function independently of other possible control units, a control unit of the system 300 may be electrically coupled or directly attached to the control unit of the vest when used in combination with the vest, or the system 300 may not include an independent control unit and the system 300 may be coupled or directly attached into a control unit of a wearable system 100). The method may include activating at least the upper first engine using the control unit 140. The control unit may control activation/deactivation/adjustment of all of the engines of the system 300. In some embodiments, the control unit 140 may be couplable to the system 300 (e.g., using a flap of material which may be used to cover and protect the control unit). The control unit 140 may be directly wired to the engines 310 and/or may be wirelessly coupled or directly attached to the engines. The control unit may use any number of known input methods (e.g., including touchpad). The control unit may be digital or analog. In some embodiments, the control unit may adjust one or more settings of the engines. The control unit may adjust the oscillation force output by the engine. The control unit may adjust an amplitude of the oscillation force output by the engine. The control unit may adjust a frequency of the oscillation force output by the engine. In some embodiments, engine parameters may be adjusted via software (e.g., a phone app) remotely (e.g., Wi-Fi, Bluetooth, etc.). In some embodiments, the engines 310 may include a frequency range from 5 Hz to 20 Hz. In some embodiments, the intensity levels dictate the frequency which generally runs at 5 Hz for the lowest setting, 13 Hz for the medium setting and 20 Hz for the highest setting.
In some embodiments, a method may include modifying the treatment parameters (e.g. amplitude, frequency, and time for each engine). Each engine may be programmed, using physical hardware control unit or software to run a custom cycle. This programming may be performed by the subject. In addition, the system may provide a physician or caregiver with the ability to prescribe a defined treatment and to inhibit the user from modifying the treatment settings (e.g. lock-out feature w/password, pin code, etc.).
In some embodiments, the method and/or system may adaptively modify the treatment protocol based on subject and/or physician feedback. For example, a subject enters mucus secretion levels after each treatment and the system adaptively optimizes the treatment settings over time.
In some embodiments, the method and/or system may monitor compliance information. For example, the system could monitor (in real-time) the treatment for each subject, including parameters run, time of treatment, time of day and any subject feedback. This could be accomplished through hardware or software (e.g. a web-based subject/physician portal which links w/Bluetooth to each vest). The information may be provided to the subject, physician, insurance company or other third-party.
In some embodiments, the system 300 may include at least one battery 150 (e.g., a battery of the system 300 may function independently of other possible batteries, a battery of the system 300 may be electrically coupled or directly attached to the battery of the vest when used in combination with the vest, or the system 300 may not include an independent battery and the system 300 may be coupled or directly attached into a battery of a wearable system 100). The method may include powering at least the upper first engines 310 using one or more batteries 150 coupled or directly attached to the wearable system. In some embodiments, a battery 150 may include a rechargeable battery and/or a disposable battery. The battery 150 may include two or more batteries. The batteries 150 may be easily swapped out whether rechargeable or disposable. The battery 150 may be coupled or directly attached to the system 300 (e.g., using a flap of material which may be used to cover and protect the battery). The system may include an adapter such that when necessary the system may be coupled or directly attached to an electrical outlet (e.g., through an electrical adapter if necessary). The system 300 may be powered using AC or DC power sources such that the system may be powered using virtually any known power source currently available.
In some embodiments, the system may be self-contained. The system may be self-contained such that a subject may wear the system 300 and move freely and in a substantially unrestricted manner. The system may be self-contained such that a subject may wear the system 300 while functioning and not physically connected to any external devices (e.g., air pumps).
Positionable Oscillating Motor Array with Potentially Disposable and/or Recyclable Portions
In some embodiments, it is advantageous to form a wearable system with one or more disposable portions. There are many advantages to having a wearable system formed from at least in part disposable portions including facilitating use of the wearable system in different environments (e.g., hospitals, clinics, etc.). Professional healthcare environments are required to constantly be vigilant regarding sanitation and cross contamination between patients. To this end medical equipment must be sanitized before being used again. However, sanitizing equipment is typically time consuming and/or expensive. As such much of the equipment used in healthcare environments which comes into direct contact with subjects is disposable (or covered by disposable sheaths). It is typically much easier and/or less expensive to throw away equipment which comes into contact with subjects as opposed to cleaning the equipment.
The method may include positioning a wearable system on a subject. The method may include adjusting the wearable system such that an oscillation force is applied to at least a first zone and to at least a second zone of the subject (e.g., and possibly more zones). In some embodiments, the oscillation force may be infinitely adjustable relative to the subject. Having an infinitely adjustable oscillation force (e.g., infinitely positionable engines) may allow customizable positioning of the oscillation force as required by the subject (e.g., as prescribed by a care giver (e.g., doctor, nurse, etc.).
In some embodiments, mobilizing secretions may include generating increased airflow velocities and/or percussive or oscillation forces resulting in cough-like shear forces. In some embodiments, mobilizing secretions may include decreasing a viscosity of at least some secretions in an airway within the subject substantially adjacent the first and/or second zone. Mobilizing secretions may assist subjects to move retained secretions from smaller airways to larger airways where they may move more easily via coughing. In some embodiments, secretions may include what is generally referred to as mucus. Mucus may include water, ions, soluble mediators, inflammatory cells, and/or secreted mucins. In some embodiments, secretions may include any fluids (e.g., excessive fluids) potentially blocking subject airways.
Depending upon the subject's specific condition one or more engines may be positioned accordingly (e.g., around the area of trouble for the subject which require treatment).
In some embodiments, a caregiver may prescribe not only the position of the engines but also the frequency of one or more of the engines. The pulse or the beat frequency of one or more of the engines may be adjusted based upon a prescribed frequency. In some embodiments, a caregiver may prescribe or program one or more or all of the engines to turn on or off.
In some embodiments, adjusting the wearable system inner harness may include adjusting fastening systems which couple the wearable system to the subject. In some embodiments, the wearable system may be adjustable at least across a chest and/or portion of a torso of a subject (e.g., as depicted in
In some embodiments, the inner harness may include a positioning system 630. The positioning system 630 may include a coupling method including, for example, a hook and loop coupling system which allows for positioning and coupling one or more portions of the oscillator system 600 to the inner harness. In some embodiments, a coupling method may include straps or pockets (e.g., as depicted in
In some embodiments, engines may be repositioned or adjusted relative to a subject using a system (e.g., by a doctor) which inhibits a subject from repositioning the engines once positioned.
The engines may be positionally coupled or directly attached to the bands and/or system using a number of means known such that the engines may be repositioned during use as appropriate for individual subjects. In some embodiments, a hook and loop system may be used to couple the engines to a wearable system such that the engines are repositionable.
In some embodiments, positioning system may include all (or substantially all) of the exterior surface of the inner harness (e.g., as depicted in
In some embodiments, they system 600 may include an outer (or second) harness 680 (e.g., as depicted in
The outer harness may allow for fewer sizes of the inner harness to be made available as the outer harness functions to tighten the engines against the subject such that the inner harness does not need to fit as snuggly. A first end of the outer harness may couple to a second end of the outer harness and/or to another portion of the outer harness during use (e.g., using hook and loop, buckles, clasps, etc.). At least a portion of the outer harness may be coupled or directly attached (e.g., permanently fixed (either directly (e.g., sewn to) or indirectly) or temporarily fixed (either directly (e.g., sewn to 690 as depicted in
In some embodiments, the outer harness may include any way of providing a compressive force to against one or more of the engines increasing the efficiency of the oscillating force applied to the subject during use (e.g., an outer harness which laces up, tightening buckles, etc.). This is in contrast to some currently known vests which are rigid, wherein the rigidity of the vest controls the placement of the engines during use.
In some embodiments, one or more engines or portions of the system may be positioned (e.g., coupled or directly attached to) the outer harness (e.g., to an inner and/or outer surface of the outer harness).
In some embodiments, the wearable system 600 may include multiple engines 640 (e.g., two or more engines, for example, as depicted in
In some embodiments, the system 600 may include a control unit 650 (e.g., as depicted in
In some embodiments, the engines 110 may include a frequency range from 5 Hz to 20 Hz. In some embodiments, the intensity levels dictate the frequency which generally runs at 5 Hz for the lowest setting, 13 Hz for the medium setting and 20 Hz for the highest setting. In some embodiments, engines may be grouped together such that frequencies produced by the grouped engines result in a superposition of the produced frequencies in order to achieve frequencies and/or intensities not achievable under normal operating parameters of the engines. For example a superpulse may be achievable, lower frequencies may be achievable. The ability to produce such a variety of different frequencies is beneficial for treating different types of lung disorders. The principle of superposition may be applied to waves whenever two (or more) waves travel through the same medium at the same time. The waves pass through each other without being disturbed. The net displacement of the medium at any point in space or time, is simply the sum of the individual wave displacements. This is true of waves pulses or continuous sine waves. For example, two sinusoidal waves with the same amplitude and frequency can add either destructively or constructively depending on their relative phase. The phase difference between the two waves may increase with time so that the effects of both constructive and destructive interference may be seen. When the two individual waves are exactly in phase the result is large amplitude. When the two waves become exactly out of phase the sum wave is zero.
For example, bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred preventing the airways from clearing mucus (mucus which is typically voluminous and relatively thin). In contrast cystic fibrosis is a genetic disorder that results in at least difficulty breathing and an inability to clear the lungs of mucus (mucus which is typically relatively thick). Different conditions result in different mucus and/or debris in a subject's lungs which may benefit from different frequencies which may be prescribed by, for example, a physician.
In some embodiments, a method may include modifying the treatment parameters (e.g. amplitude, frequency, and time for each engine). Each engine may be programmed, using physical hardware control unit or software to run a custom cycle. This programming may be performed according to each subject. In addition, the system may provide a physician or caregiver with the ability to prescribe a defined treatment and/or to inhibit the user from modifying the treatment settings (e.g. lock-out feature w/password, pin code, etc.). Each of the motors may be individually programmable (e.g., length of run time, type of vibration (e.g., constant, pulsing, etc.), frequency, amplitude, etc.).
In some embodiments, the method and/or system may adaptively modify the treatment protocol based on subject and/or physician feedback. For example, a subject enters mucus secretion levels after each treatment and the system adaptively optimizes the treatment settings over time.
In some embodiments, the method and/or system may monitor compliance information. For example, the system could monitor (in real-time) the treatment for each subject, including parameters run, time of treatment, time of day and any subject feedback. This could be accomplished through hardware or software (e.g. a web-based subject/physician portal which links w/Bluetooth to each vest). The information may be provided to the subject, physician, insurance company or other third-party.
In some embodiments, the system 600 may include at least one battery 660. The method may include powering the engines 640 using one or more batteries 660 coupled or directly attached to the inner harness of the wearable system. In some embodiments, a battery 660 may include a rechargeable battery and/or a disposable battery. The battery 660 may include two or more batteries. The batteries 660 may be easily swapped out whether rechargeable or disposable. The battery 660 may be coupled or directly attached to the system 600 (e.g., using a hook and loop strip 630 as depicted in
In some embodiments, the system 600 may include a system of electrical couplings 670. Electrical couplings 670 may couple control unit 650 and/or battery 660 to engines 640 (e.g., as depicted in
In some embodiments, the system may be self-contained. The system may be self-contained such that a subject may wear the system 600 and move freely and in a substantially unrestricted manner. The system may be self-contained such that a subject may wear the system 600 while functioning and not physically connected to any external devices (e.g., air pumps).
In some embodiments, all, substantially all, or at least one portion of the system 600 may be disposable or recyclable. Making portions of the system 600 disposable may be disposable due to, for example, that much of the equipment used in healthcare environments which comes into direct contact with subjects is disposable (or covered by disposable sheaths). It is typically much easier and/or less expensive to throw away equipment which comes into contact with subjects as opposed to cleaning the equipment. In some embodiments, the inner wearable harness is disposable. In some embodiments, the outer wearable harness is disposable. In some embodiments, at least some of the plurality of engines are disposable. In some embodiments, the inner and/or outer harness and the engines may be disposable.
In some embodiments, one or more portions of the system 600 are recyclable. For example self-contained portions of the system (e.g., engines 640) may be recyclable in order to reduce waste.
In some embodiments, one or more portions of the systems describe herein may include antimicrobial coatings (e.g., in fabrics of the vests). In some embodiments, one or more portions of the systems described herein may be able to withstand one or more common medical sterilization techniques (e.g., high temperature, high pressure, chemical, etc.). In some embodiments, one or more portions (e.g., in fabrics of the vests or the containers for one or more engines) may include an impervious materials, coatings, or linings such that one or more portions of the system are protected from or at least inhibited from exposure to one or more contaminants. For example, a lining or material may be substantially impervious to water or blood borne pathogens or contaminants. For example, a lining or material may be substantially impervious to gasses and/or air borne pathogens or contaminants. In some embodiments, a container such as a positionable engine container 645 may include an impervious or impermeable lining which inhibits contamination of an engine positioned in the container such that the engine may be more easily recycled.
In this patent, certain U.S. patents, U.S. patent applications, and other materials (e.g., articles) have been incorporated by reference. The text of such U.S. patents, U.S. patent applications, and other materials is, however, only incorporated by reference to the extent that no conflict exists between such text and the other statements and drawings set forth herein. In the event of such conflict, then any such conflicting text in such incorporated by reference U.S. patents, U.S. patent applications, and other materials is specifically not incorporated by reference in this patent.
Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as the presently preferred embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention as described in the following claims.
This application is a claims priority to U.S. Provisional Patent Application No. 62/060,772 entitled “CHEST WALL OSCILLATION VEST” filed on Oct. 7, 2014, U.S. Provisional Patent Application No. 62/101,131 entitled “SELF-CONTAINED PORTABLE HIGH FREQUENCY PHYSIOLOGICAL OSCILLATOR” filed on Jan. 8, 2015, and U.S. Provisional Patent Application No. 62/183,819 entitled “SELF-CONTAINED PORTABLE POSITIONABLE OSCILLATING MOTOR ARRAY” filed on Jun. 24, 2015, all of which are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3053250 | Stubbs | Sep 1962 | A |
3310050 | Goldfarb | Mar 1967 | A |
3351053 | Stuttle | Nov 1967 | A |
3612046 | Gaylord | Oct 1971 | A |
4216766 | Duykers et al. | Aug 1980 | A |
4257408 | Ramey | Mar 1981 | A |
4979502 | Hunt | Dec 1990 | A |
5235967 | Arbisi et al. | Aug 1993 | A |
5273028 | McLeod | Dec 1993 | A |
5363863 | Lelli et al. | Nov 1994 | A |
5437617 | Heinz et al. | Aug 1995 | A |
5884338 | Golde | Mar 1999 | A |
6152855 | Dean, Jr. | Nov 2000 | A |
6193678 | Brannon | Feb 2001 | B1 |
6329638 | Bloodworth | Dec 2001 | B1 |
6471663 | Van Brunt et al. | Oct 2002 | B1 |
6514200 | Khouri | Feb 2003 | B1 |
6926667 | Khouri | Aug 2005 | B2 |
6962277 | Quintana et al. | Nov 2005 | B2 |
7147610 | Maalouf | Dec 2006 | B2 |
7207953 | Goicaj | Apr 2007 | B1 |
7374550 | Hansen et al. | May 2008 | B2 |
D608983 | Myers | Feb 2010 | S |
7890342 | Yruko et al. | Feb 2011 | B1 |
7954900 | Shantha et al. | Jun 2011 | B2 |
8332236 | Yurko et al. | Dec 2012 | B2 |
8460223 | Huster et al. | Jun 2013 | B2 |
8786999 | Locke | Jul 2014 | B2 |
8870796 | Hoffmann | Oct 2014 | B2 |
8950207 | Raines et al. | Feb 2015 | B2 |
9289350 | Helgeson et al. | Mar 2016 | B2 |
9549869 | DeVlieger et al. | Jan 2017 | B2 |
9839553 | Bannister | Dec 2017 | B2 |
9895287 | Shockley et al. | Feb 2018 | B2 |
9907488 | Barduson | Mar 2018 | B2 |
9907725 | Shockley et al. | Mar 2018 | B2 |
9956134 | Shockley et al. | May 2018 | B2 |
9968511 | Huster et al. | May 2018 | B2 |
10034813 | Silver | Jul 2018 | B1 |
10039692 | Nickelson | Aug 2018 | B2 |
10159623 | Leftly | Dec 2018 | B2 |
10251810 | Shockley et al. | Apr 2019 | B2 |
20020013516 | Freyre et al. | Jan 2002 | A1 |
20030028132 | Bastia et al. | Feb 2003 | A1 |
20030199899 | Boecker | Oct 2003 | A1 |
20040039317 | Souney et al. | Feb 2004 | A1 |
20040082237 | Farmer et al. | Apr 2004 | A1 |
20040133133 | Dreimann et al. | Jul 2004 | A1 |
20040158177 | Van Brunt et al. | Aug 2004 | A1 |
20050054958 | Hoffmann | Mar 2005 | A1 |
20050126578 | Garrison et al. | Jun 2005 | A1 |
20050234372 | Hansen et al. | Oct 2005 | A1 |
20050235988 | Hansen et al. | Oct 2005 | A1 |
20060009684 | Kim | Jan 2006 | A1 |
20060015045 | Zets et al. | Jan 2006 | A1 |
20060075537 | Tsai | Apr 2006 | A1 |
20060218692 | Lamarque | Oct 2006 | A1 |
20070197881 | Wolf et al. | Aug 2007 | A1 |
20070239087 | Kivisto | Oct 2007 | A1 |
20080000477 | Huster et al. | Jan 2008 | A1 |
20080027363 | Brueckmann et al. | Jan 2008 | A1 |
20080086062 | Hansen et al. | Apr 2008 | A1 |
20080108914 | Brouqueyre | May 2008 | A1 |
20080275343 | Hoffmann | Nov 2008 | A1 |
20090069728 | Hoffman et al. | Mar 2009 | A1 |
20090177222 | Brown et al. | Jul 2009 | A1 |
20090234256 | Helgeson et al. | Sep 2009 | A1 |
20090255022 | Smith et al. | Oct 2009 | A1 |
20100071919 | Muzzy et al. | Mar 2010 | A1 |
20100113993 | Davis et al. | May 2010 | A1 |
20100292568 | Droitcour et al. | Nov 2010 | A1 |
20110139836 | Klann | Jun 2011 | A1 |
20110162121 | Klann | Jul 2011 | A1 |
20110166486 | Kumanomido | Jul 2011 | A1 |
20120022415 | Mullen | Jan 2012 | A1 |
20120060255 | Raviv | Mar 2012 | A1 |
20120185999 | Raviv | Jul 2012 | A1 |
20120186000 | Raviv | Jul 2012 | A1 |
20120259255 | Tomlinson et al. | Oct 2012 | A1 |
20120291798 | Park et al. | Nov 2012 | A1 |
20130037531 | Gray | Feb 2013 | A1 |
20130211294 | Bohris | Aug 2013 | A1 |
20130261518 | Hansen et al. | Oct 2013 | A1 |
20130289455 | Clapp et al. | Oct 2013 | A1 |
20130289456 | Cang Guo et al. | Oct 2013 | A1 |
20140005579 | Drlik et al. | Jan 2014 | A1 |
20140012167 | DeVlieger et al. | Jan 2014 | A1 |
20140150791 | Bimkrant et al. | Jun 2014 | A1 |
20140257151 | Chikkanaravangala et al. | Sep 2014 | A1 |
20140257153 | Nickelson | Sep 2014 | A1 |
20140358189 | Mashiach et al. | Dec 2014 | A1 |
20150265209 | Zhang | Sep 2015 | A1 |
20150272236 | Chen | Oct 2015 | A1 |
20150272805 | Burnett et al. | Oct 2015 | A1 |
20150296909 | Sachs | Oct 2015 | A1 |
20150305974 | Ehrenreich et al. | Oct 2015 | A1 |
20150374578 | Matsuura | Dec 2015 | A1 |
20160089571 | Wesley et al. | Mar 2016 | A1 |
20160095782 | Shockley et al. | Apr 2016 | A1 |
20160095783 | Shockley et al. | Apr 2016 | A1 |
20160095791 | Shockley et al. | Apr 2016 | A1 |
20160095792 | Shockley et al. | Apr 2016 | A1 |
20160095793 | Shockley et al. | Apr 2016 | A1 |
20160095790 | Shockley et al. | Jun 2016 | A1 |
20160306932 | Fateh et al. | Oct 2016 | A1 |
20170000686 | Shockley et al. | Jan 2017 | A1 |
20170000687 | Shockley et al. | Jan 2017 | A1 |
20170095400 | Shockley et al. | Apr 2017 | A1 |
20170015697 | Shockley et al. | Jun 2017 | A1 |
20170177818 | Eustis | Jun 2017 | A1 |
20180092801 | Shockley et al. | Apr 2018 | A1 |
20190038502 | Shockley et al. | Feb 2019 | A1 |
Number | Date | Country |
---|---|---|
202008015893 | Jul 2009 | DE |
2010071919 | Jul 2010 | WO |
2011094883 | Aug 2011 | WO |
2013052817 | Apr 2013 | WO |
2016057527 | Apr 2016 | WO |
2018093993 | May 2018 | WO |
Entry |
---|
Co-Pending U.S. Appl. No. 15/728,887 entitled, “Systems and Methods for Monitoring a Subject's Effective Use of a Self-Contained Portable Positionable Oscillating Motor Array” to Shockley et al. filed Oct. 10, 2017. |
NPL10_Hill-Rom Monarch TM Airway Clearance System Pamphlet “Take More Control of Your Life” Apr. 13, 2017. |
NPL09_International Preliminary Report on Patentability for PCT/US2015/054261 dated Apr. 11, 2017. pp. 18. |
Non Final Office Action for U.S. Appl. No. 14/876,479 dated Oct. 5, 2017. |
Non Final Office Action for U.S. Appl. No. 15/266,465 dated Dec. 20, 2016. |
Final Office Action for U.S. Appl. No. 15/266,465 dated Jul. 3, 2017. |
Non Final Office Action for U.S. Appl. No. 15/266,496 dated Dec. 2, 2016. |
Final Office Action for U.S. Appl. No. 15/266,496 dated Jun. 14, 2017. |
Non Final Office Action for U.S. Appl. No. 15/266,521 dated Dec. 29, 2016. |
Final Office Action for U.S. Appl. No. 15/266,521 dated Jun. 30, 2017. |
International Biophysics Corporation AffloVest White Paper, “AffloVest Answering Needs: The Role of the AffloVest in the Respiratory Market”, Oct. 2013. |
The VibraVest by OxyCare GMbH product brochure. May 2012. |
Cooper, M. “An evidence-based study of adolescents with cystic fibrosis demonstrated that AffloVest® by International Biophysics contributed to improved lung function scores” Chicago, Illinois. Apr. 6, 2015. |
International Biophysics Corporation “Clinical Study of the AffloVest as a High Frequency Chest Wall Oscillation Device” Mar. 2013. |
International Biophysics Corporation AffloVest Pamphlet. Oct. 2013. |
Co-Pending U.S. Appl. No. 14/876,472 entitled, “Self-Contained Portable Positionable Oscillating Motor Array” to Shockley et al. filed Oct. 6, 2015. |
Co-Pending U.S. Appl. No. 14/876,476 entitled, “Method of Clearing a Biological Airway Using a Self-Contained Portable Positionable Oscillating Motor Array” to Shockley et al. filed Oct. 6, 2015. |
Co-Pending U.S. Appl. No. 14/876,487 entitled, “Kit for Clearing a Biological Airway Including a Self-Contained Portable Positionable Oscillating Motor Array” to Shockley et al. filed Oct. 6, 2015. |
Co-Pending U.S. Appl. No. 14/876,494 entitled, “Flexible Vest Including a Positionable Oscillating Motor Array” to Shockley et al. filed Oct. 6, 2015. |
Co-Pending U.S. Appl. No. 14/876,504 entitled, “Self-Contained Portable Positionable Oscillating Motor Array Including Disposable and/or Recyclable Portions” to Shockley et al. filed Oct. 6, 2015. |
Co-Pending U.S. Appl. No. 14/876,507 entitled, “Self-Contained Portable Positionable Oscillating Motor Array Including an Outer Harness Providing a Compressive Force” to Shockley et al. filed Oct. 6, 2015. |
Non Final Office Action for U.S. Appl. No. 14/876,472 dated Dec. 15, 2017. |
Notice of Allowance for U.S. Appl. No. 15/266,465 dated Oct. 30, 2017. |
Notice of Allowance for U.S. Appl. No. 15/266,496 dated Dec. 21, 2017. |
Notice of Allowance for U.S. Appl. No. 15/266,521 dated Sep. 26, 2017. |
Non Final Office Action for U.S. Appl. No. 15/728,887 dated Feb. 28, 2018. |
NPL11 International Search Report and Written Opinion for PCT/US17/61935 dated Feb. 6, 2018. pp. 12. |
International Search Report and Written Opinion for PCT/US15/54261 dated Jan. 7, 2016. pp. 20. |
Tackell, M. W. et al., “Lung function improvement with AffloVest® HFCWO use: a clinician's perspective on PFT score data from 25 patients with cystic fibrosis.” May 2016. |
AffloVest, International Biophysics Press Release, PRNewswire, May 11, 2016. |
Notice of Allowance for U.S. Appl. No. 14/876,507 dated Jul. 23, 2018. |
Final Office Action for U.S. Appl. No. 14/876,479 dated Jun. 13, 2018. |
Final Office Action for U.S. Appl. No. 14/876,472 dated Jun. 14, 2018. |
Non Final Office Action for U.S. Appl. No. 14/876,487 dated Apr. 6, 2018. |
Non Final Office Action for U.S. Appl. No. 14/876,507 dated Apr. 6, 2018. |
NPL12_Extended European Search Report for European Application No. 15848394.1-1126 dated May 11, 2018. |
Advisory Action for U.S. Appl. No. 14/876,472 dated Aug. 24, 2018. |
Non Final Office Action for U.S. Appl. No. 14/876,472 dated Oct. 9, 2018. |
Advisory Action for U.S. Appl. No. 14/876,479 dated Aug. 24, 2018. |
Non Final Office Action for U.S. Appl. No. 14/876,479 dated Nov. 1, 2018. |
Final Office Action for U.S. Appl. No. 14/876,487 dated Sep. 6, 2018. |
Non Final Office Action for U.S. Appl. No. 14/876,494 dated Oct. 4, 2018. |
Final Office Action for U.S. Appl. No. 15/728,887 dated Sep. 6, 2018. |
Non Final Office Action for U.S. Appl. No. 14/876,487 dated Jan. 2, 2019. |
Notice of Allowance for U.S. Appl. No. 14/876,507 dated Nov. 27, 2018. |
Advisory Action for U.S. Appl. No. 15/728,887 dated Nov. 28, 2018. |
Non Final Office Action for U.S. Appl. No. 15/728,887 dated Jan. 7, 2019. |
Non Final Office Action for U.S. Appl. No. 16/157,631 dated Jan. 2, 2019. |
Co-Pending U.S. Appl. No. 15/266,465 entitled, “Self-Contained Portable Positionable Oscillating Motor Array System” to Shockley et al. filed Sep. 15, 2016. |
Co-Pending U.S. Appl. No. 15/266,496 entitled, “Method of Clearing a Biological Airway Using a Self-Contained Portable Positionable Oscillating Motor Array” to Shockley et al. filed Sep. 15, 2016. |
Co-Pending U.S. Appl. No. 15/266,521 entitled, “Kit for Clearing a Biological Airway Including a Self-Contained Portable Positionable Oscillating Motor Array” to Shockley et al. filed Sep. 15, 2016. |
Co-Pending U.S. Appl. No. 15/353,383 entitled, :Systems and Methods for Monitoring a Subject'S Effective Use of a Self-Contained Portable Positionable Oscillating Motor Array to Shockley et al. filed Nov. 16, 2016. |
Non Final Office Action for U.S. Appl. No. 14/876,472 dated Sep. 30, 2019. |
Final Office Action for U.S. Appl. No. 14/876,472 dated Mar. 12, 2020. |
International Search Report and Written Opinion for PCT/US2019/055183 dated Dec. 5, 2019; 11 pages. |
Co-Pending U.S. Appl. No. 16/157,631 entitled: “Systems and Methods for Effective Reuse of a Self-Contained Portable Positionable Oscillating Motor Array” to Shockley et al. filed Oct. 11, 2018. |
Notice of Allowance for U.S. Appl. No. 16/157,631 dated May 14, 2020. |
Advisory Action for U.S. Appl. No. 14/876,494 dated Jul. 1, 2019. |
Non Final Office Action for U.S. Appl. No. 14/876,494 dated Sep. 20, 2019. |
Final Office Action for U.S. Appl. No. 14/876,494 dated Feb. 21, 2020. |
Final Office Action for U.S. Appl. No. 14/876,504 dated Sep. 17, 2019. |
Advisory Action for U.S. Appl. No. 14/876,504 dated Dec. 4, 2019. |
Non-Final Office Action for U.S. Appl. No. 14/876,504 dated Jan. 8, 2020. |
Non-Final Office Action for U.S. Appl. No. 15/353,383 dated Feb. 24, 2020. |
Office Action for Australian Application No. 2015328220 dated Jul. 1, 2019. |
Office Action for European Application No. 15848394.1-1126 dated Apr. 21, 2020. |
Non Final Office Action for U.S. Appl. No. 15/728,887 dated Oct. 1, 2019. |
Notice of Allowance for U.S. Appl. No. 15/728,887 dated Feb. 11, 2020. |
International Preliminary Report on Patentability for PCT/US17/61935 dated Feb. 14, 2019. |
Supplemental Search Report for European Application No. 17872163.5 dated May 8, 2020. |
Advisory Action for U.S. Appl. No. 16157631 dated Nov. 21, 2019. |
Final Office Action for U.S. Appl. No. 14/876,479 dated Apr. 12, 2019. |
Advisory Action for U.S. Appl. No. 14/876,479 dated Jul. 1, 2019. |
Non Final Office Action for U.S. Appl. No. 14/876,479 dated Sep. 30, 2019. |
Non Final Office Action for U.S. Appl. No. 14/876,479 dated Mar. 13, 2020. |
Final Office Action for U.S. Appl. No. 14/876,494 dated Apr. 11, 2019. |
Non-Final Office Action for U.S. Appl. No. 14/876,504 dated Mar. 28, 2019. |
Final Office Action for U.S. Appl. No. 15/728,887 dated Jun. 13, 2019. |
Final Office Action for U.S. Appl. No. 16/157,631 dated Jul. 1, 2019. |
Non-Final Office Action for U.S. Appl. No. 14/876,504 dated Jan. 1, 2020. |
Number | Date | Country | |
---|---|---|---|
20160095791 A1 | Apr 2016 | US |
Number | Date | Country | |
---|---|---|---|
62060772 | Oct 2014 | US | |
62101131 | Jan 2015 | US | |
62183819 | Jun 2015 | US |